“Deucravacitinib in Plaque Psoriasis: Maintenance of Response Over 4 Years in the Phase 3 POETYK PSO-1, PSO-2, and LTE Trials”. SKIN The Journal of Cutaneous Medicine, vol. 8, no. 4, July 2024, p. s407, https://doi.org/10.25251/skin.8.supp.407.